SCHEMBL8937478

SCHEMBL8937478

COc1ccc(C(=CC(=O)N2CCN(C(=O)c3cc(OC)c(O)c(OC)c3)CC2)c2ccccc2Cl)cc1

nearest known ligand 0.52

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
ABL1 P00519 1/20 0.48
BCR P11274 1/20 0.48
GPR183 P32249 2/20 0.47
KMT2A Q03164 4/20 0.46
MEN1 O00255 2/20 0.46
CYP1A2 P05177 1/20 0.45
LMNA P02545 1/20 0.44
MAPT P10636 1/20 0.44
TP53 P04637 1/20 0.44
MGLL Q99685 2/20 0.43
DRD2 P14416 1/20 0.43
DRD3 P35462 1/20 0.43
SPTLC2 O15270 4/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8937674 1.00 ALDH1A1 (0.52) ALDH1A1L3MBTL1ABL1BCRGPR183
SCHEMBL8937669 1.00 ALDH1A1 (0.52) ALDH1A1L3MBTL1ABL1BCRGPR183
SCHEMBL8937498 0.92 ALDH1A1 (0.64) ALDH1A1L3MBTL1ABL1BCRGPR183
SCHEMBL8937637 0.92 ALDH1A1 (0.64) ALDH1A1L3MBTL1ABL1BCRGPR183
SCHEMBL8937500 0.92 ALDH1A1 (0.64) ALDH1A1L3MBTL1ABL1BCRGPR183
SCHEMBL8937589 0.89 ALDH1A1 (0.53) ALDH1A1L3MBTL1ABL1BCRGPR183
SCHEMBL8937700 0.89 ALDH1A1 (0.53) ALDH1A1L3MBTL1ABL1BCRGPR183
SCHEMBL8937586 0.89 ALDH1A1 (0.53) ALDH1A1L3MBTL1ABL1BCRGPR183
SCHEMBL8937494 0.85 ALDH1A1 (0.61) ALDH1A1L3MBTL1GPR183KMT2AMEN1
SCHEMBL8937496 0.85 ALDH1A1 (0.61) ALDH1A1L3MBTL1GPR183KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5559109-A Method of treating a PAF-mediated pathology or for treating or preventing psoriasis, nephritis, asthma or shock by administering a PAF antagonist SANKKO COMPANY, LIMITED (JP) 1996-09-24 US claimed
US-5559109-A Method of treating a PAF-mediated pathology or for treating or preventing psoriasis, nephritis, asthma or shock by administering a PAF antagonist SANKKO COMPANY, LIMITED (JP) 1996-09-24 US disclosed
US-5369106-A N-acryloylpiperazine derivatives, their preparation and their use of PAF antagonists SANKYO COMPANY, LIMITED (JP) 1994-11-29 US disclosed
US-5192766-A Platelet activating factor antagonist SANKYO COMPANY, LIMITED (JP) 1993-03-09 US disclosed